Pre-Market Activity Shows Gains For Amgen (AMGN)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
(
) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Amgen as such a stock due to the following factors:
- AMGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $446.1 million.
- AMGN traded 11,774 shares today in the pre-market hours as of 9:29 AM.
- AMGN is up 2.4% today from yesterday's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMGN with the Ticky from Trade-Ideas. See the FREE profile for AMGN NOW at Trade-Ideas
More details on AMGN:
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The stock currently has a dividend yield of 2.1%. AMGN has a PE ratio of 22.8. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.
The average volume for Amgen has been 3.6 million shares per day over the past 30 days. Amgen has a market cap of $115.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.58 and a short float of 1.5% with 3.65 days to cover. Shares are down 4.1% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Amgen as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
Highlights from the ratings report include:
- Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
- AMGEN INC has improved earnings per share by 26.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, AMGEN INC increased its bottom line by earning $6.70 versus $6.65 in the prior year. This year, the market expects an improvement in earnings ($9.32 versus $6.70).
- AMGN's revenue growth trails the industry average of 36.4%. Since the same quarter one year prior, revenues slightly increased by 6.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The gross profit margin for AMGEN INC is currently very high, coming in at 89.83%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 24.27% trails the industry average.
- You can view the full Amgen Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null